ClinicalTrials.gg
CompletedNCT01332188AC-170Updated Aug 30, 2017Results posted

Efficacy of AC-170 for the Treatment of Allergic Conjunctivitis in the Conjunctival Allergen Challenge (CAC) Model

A Phase 2/3 interventional study of AC-170 0.05% and AC-170 0.1% in Allergic Conjunctivitis, sponsored by Aciex Therapeutics, Inc.. Completed at 1 site in United States. Open to participants aged 10 Years and older. Per ClinicalTrials.gov, last updated 2017-08-30.

Sponsored by Aciex Therapeutics, Inc. · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
101
Allocation
Randomized
Ages
10 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 95 studies in Conjunctivitis, Allergic with a site in United States — 6 open to participants now, 7 under way, 2 of them phase 3. Conjunctivitis, Allergic · United States.

Enrollment
39th of 90
101 · median 94
Started
2011
with 9 others
Phase 2/3
2 of 95
none open now
Registered
39th of 95
by date
Lead sponsor
6 of 95
Aciex Therapeutics, Inc.

Among the 95 studies in Conjunctivitis, Allergic with a site in United States, this one is the 39th largest by enrollment of the 90 interventional ones that give a count, is one of 10 that started in 2011, is one of 2 in phase 2/3, and was the 39th registered.

Conjunctivitis, Allergic

211 studies on the registry are indexed under Conjunctivitis, Allergic; 19 are open to participants now.

Browse Conjunctivitis, Allergic studies →

Open to participants now

6 of the 95 studies in Conjunctivitis, Allergic with a site in United States are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 12 Conjunctivitis, Allergic studies recruiting now, 8 (67%) set no upper age limit and 4 (33%) stop at 75 or younger; 4 take children under 18; 2 take healthy volunteers.

This study: 10 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 95 studies in Conjunctivitis, Allergic with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy of different concentrations of AC-170 compared to vehicle in the prevention of the signs and symptoms of allergic conjunctivitis in the conjunctival allergen challenge (CAC) Model.

03

Conditions studied

  • Allergic Conjunctivitis
04

Who can participate

Ages eligible
10 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Positive bilateral conjunctival allergen challenge (CAC) reaction

Exclusion criteria

Exclusion Criteria:

  • Known or sensitivities to the study medication or its components.
  • Any ocular condition that, in the opinion of the investigator, could affect the subjects safety or trial parameters.
  • Use of disallowed medications during the period indicated prior to the study enrollment or during the study.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
101 participants (actual)

Study arms

  • Experimental
    AC-170 0.05%

    Drug: AC-170 0.05%

  • Experimental
    AC-170 0.1%

    Drug: AC-170 0.1%

  • Experimental
    AC-170 0.24%

    Drug: AC-170 0.24%

  • Placebo comparator
    AC-170 0%

    Drug: AC-170 0%

Interventions

  • 1 drop in each eye at 3 separate times during a 21 day period

  • 1 drop in each eye at 3 separate times during a 21 day period

  • 1 drop in each eye at 3 separate times during a 21 day period

  • DrugAC-170 0%

    1 drop in each eye at 3 separate times during a 21 day period

06

What researchers measure

Primary outcomes

  1. Ocular Itching at Duration of Action (16 Hours Post-dose)

    A treatment efficacy CAC was performed 16 hours after drop instillation. Ocular itching was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of ocular itching score over both eyes was analyzed.

    Time frame: 3, 5, 7 minutes post-CAC

  2. Ocular Itching at Duration of Action (24 Hours Post-dose)

    A treatment efficacy CAC was performed 24 hours after drop instillation. Ocular itching was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of ocular itching score over both eyes was analyzed.

    Time frame: 3, 5, 7 minutes post-CAC

  3. Ocular Itching at Onset of Action (15 Minutes Post-dose)

    A treatment efficacy CAC was performed 15 minutes after drop instillation. Ocular itching was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of ocular itching score over both eyes was analyzed.

    Time frame: 3, 5, 7 minutes post-CAC

  4. Conjunctival Redness at Duration of Action (16 Hours Post-dose)

    A treatment efficacy CAC was performed 16 hours after drop instillation. Conjunctival Redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of conjunctival redness score over both eyes was analyzed.

    Time frame: 7, 15, 20 minutes post-CAC

  5. Conjunctival Redness at Duration of Action (24 Hours Post-dose)

    A treatment efficacy CAC was performed 24 hours after drop instillation. Conjunctival Redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of conjunctival redness score over both eyes was analyzed.

    Time frame: 7, 15, 20 minutes post-CAC

  6. Conjunctival Redness at Onset of Action (15 Minutes Post-dose)

    A treatment efficacy CAC was performed 15 minutes after drop instillation. Conjunctival Redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of conjunctival redness score over both eyes was analyzed.

    Time frame: 7, 15, 20 minutes post-CAC

Secondary outcomes

  1. Ciliary Redness at Duration of Action (16 Hours Post-dose)

    A treatment efficacy CAC was performed 16 hours after drop instillation. Ciliary Redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of ciliary redness score over both eyes was analyzed.

    Time frame: 7, 15, 20 minutes post-CAC

  2. Ciliary Redness at Duration of Action (24 Hours Post-dose)

    A treatment efficacy CAC was performed 24 hours after drop instillation. Ciliary Redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of ciliary redness score over both eyes was analyzed.

    Time frame: 7, 15, 20 minutes post-CAC

  3. Ciliary Redness at Onset of Action (15 Minutes Post-dose)

    A treatment efficacy CAC was performed 15 minutes after drop instillation. Ciliary Redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of ciliary redness score over both eyes was analyzed.

    Time frame: 7, 15, 20 minutes post-CAC

  4. Episcleral Redness at Duration of Action (16 Hours Post-dose)

    A treatment efficacy CAC was performed 16 hours after drop instillation. Episcleral Redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of episcleral redness score over both eyes was analyzed.

    Time frame: 7, 15, 20 minutes post-CAC

  5. Episcleral Redness at Duration of Action (24 Hours Post-dose)

    A treatment efficacy CAC was performed 24 hours after drop instillation. Episcleral Redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of episcleral redness score over both eyes was analyzed.

    Time frame: 7, 15, 20 minutes post-CAC

  6. Episcleral Redness at Onset of Action (15 Minutes Post-dose)

    A treatment efficacy CAC was performed 15 minutes after drop instillation. Episcleral Redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of episcleral redness score over both eyes was analyzed.

    Time frame: 7, 15, 20 minutes post-CAC

  7. Chemosis at Duration of Action (16 Hours Post-dose)

    A treatment efficacy CAC was performed 16 hours after drop instillation. Chemosis was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of chemosis score over both eyes was analyzed.

    Time frame: 7, 15, 20 minutes post-CAC

  8. Chemosis at Duration of Action (24 Hours Post-dose)

    A treatment efficacy CAC was performed 24 hours after drop instillation. Chemosis was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of chemosis score over both eyes was analyzed.

    Time frame: 7, 15, 20 minutes post-CAC

  9. Chemosis at Onset of Action (15 Minutes Post-dose)

    A treatment efficacy CAC was performed 15 minutes after drop instillation. Chemosis was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of chemosis score over both eyes was analyzed.

    Time frame: 7, 15, 20 minutes post-CAC

  10. Eyelid Swelling at Duration of Action (16 Hours Post-dose)

    A treatment efficacy CAC was performed 16 hours after drop instillation. Eyelid swelling was assessed by the patient on a 0-3 scale (0=none to 3=severe). Average of eyelid swelling score over both eyes was analyzed.

    Time frame: 7, 15, 20 minutes post-CAC

  11. Eyelid Swelling at Duration of Action (24 Hours Post-dose)

    A treatment efficacy CAC was performed 24 hours after drop instillation. Eyelid swelling was assessed by the patient on a 0-3 scale (0=none to 3=severe). Average of eyelid swelling score over both eyes was analyzed.

    Time frame: 7, 15, 20 minutes post-CAC

  12. Eyelid Swelling at Onset of Action (15 Minutes Post-dose)

    A treatment efficacy CAC was performed 15 minutes after drop instillation. Eyelid swelling was assessed by the patient on a 0-3 scale (0=none to 3=severe). Average of eyelid swelling score over both eyes was analyzed.

    Time frame: 7, 15, 20 minutes post-CAC

  13. Tearing at Duration of Action (16 Hours Post-dose)

    A treatment efficacy CAC was performed 16 hours after drop instillation. Tearing was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of tearing score over both eyes was analyzed.

    Time frame: 7, 15, 20 minutes post-CAC

  14. Tearing at Duration of Action (24 Hours Post-dose)

    A treatment efficacy CAC was performed 24 hours after drop instillation. Tearing was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of tearing score over both eyes was analyzed.

    Time frame: 7, 15, 20 minutes post-CAC

  15. Tearing at Onset of Action (15 Minutes Post-dose)

    A treatment efficacy CAC was performed 15 minutes after drop instillation. Tearing was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of tearing score over both eyes was analyzed.

    Time frame: 7, 15, 20 minutes post-CAC

  16. Rhinorrhea at Duration of Action (16 Hours Post-dose)

    A treatment efficacy CAC was performed 16 hours after drop instillation. Rhinorrhea was assessed by the patient on a 0-4 scale (0=none to 4=severe). Rhinorrhea score for each time point was analyzed.

    Time frame: 7, 15, 20 minutes post-CAC

  17. Rhinorrhea at Duration of Action (24 Hours Post-dose)

    A treatment efficacy CAC was performed 24 hours after drop instillation. Rhinorrhea was assessed by the patient on a 0-4 scale (0=none to 4=severe). Rhinorrhea score for each time point was analyzed.

    Time frame: 7, 15, 20 minutes post-CAC

  18. Rhinorrhea at Onset of Action (15 Minutes Post-dose)

    A treatment efficacy CAC was performed 15 minutes after drop instillation. Rhinorrhea was assessed by the patient on a 0-4 scale (0=none to 4=severe). Rhinorrhea score for each time point was analyzed.

    Time frame: 7, 15, 20 minutes post-CAC

  19. Nasal Pruritus at Duration of Action (16 Hours Post-dose)

    A treatment efficacy CAC was performed 16 hours after drop instillation. Nasal Pruritus was assessed by the patient on a 0-4 scale (0=none to 4=severe). Nasal Pruritus score for each time point was analyzed.

    Time frame: 7, 15, 20 minutes post-CAC

  20. Nasal Pruritus at Duration of Action (24 Hours Post-dose)

    A treatment efficacy CAC was performed 24 hours after drop instillation. Nasal Pruritus was assessed by the patient on a 0-4 scale (0=none to 4=severe). Nasal Pruritus score for each time point was analyzed.

    Time frame: 7, 15, 20 minutes post-CAC

  21. Nasal Pruritus at Onset of Action (15 Minutes Post-dose)

    A treatment efficacy CAC was performed 15 minutes after drop instillation. Nasal Pruritus was assessed by the patient on a 0-4 scale (0=none to 4=severe). Nasal Pruritus score for each time point was analyzed.

    Time frame: 7, 15, 20 minutes post-CAC

  22. Ear or Palate Pruritus at Duration of Action (16 Hours Post-dose)

    A treatment efficacy CAC was performed 16 hours after drop instillation. Ear or Palate Pruritus was assessed by the patient on a single 0-4 scale (0=none to 4=severe). Ear or Palate Pruritus score for each time point was analyzed.

    Time frame: 7, 15, 20 minutes post-CAC

  23. Ear or Palate Pruritus at Duration of Action (24 Hours Post-dose)

    A treatment efficacy CAC was performed 24 hours after drop instillation. Ear or Palate Pruritus was assessed by the patient on a single 0-4 scale (0=none to 4=severe). Ear or Palate Pruritus score for each time point was analyzed.

    Time frame: 7, 15, 20 minutes post-CAC

  24. Ear or Palate Pruritus at Onset of Action (15 Minutes Post-dose)

    A treatment efficacy CAC was performed 15 minutes after drop instillation. Ear or Palate Pruritus was assessed by the patient on a single 0-4 scale (0=none to 4=severe). Ear or Palate Pruritus score for each time point was analyzed.

    Time frame: 7, 15, 20 minutes post-CAC

  25. Nasal Congestion at Onset of Action (16 Hours Post-dose)

    A treatment efficacy CAC was performed 16 hours after drop instillation. Nasal Congestion was assessed by the patient on a 0-4 scale (0=none to 4=severe). Nasal Congestion score for each time point was analyzed.

    Time frame: 7, 15, 20 minutes post-CAC

  26. Nasal Congestion at Duration of Action (24 Hours Post-dose)

    A treatment efficacy CAC was performed 24 hours after drop instillation. Nasal Congestion was assessed by the patient on a 0-4 scale (0=none to 4=severe). Nasal Congestion score for each time point was analyzed.

    Time frame: 7, 15, 20 minutes post-CAC

  27. Nasal Congestion at Onset of Action (15 Minutes Post-dose)

    A treatment efficacy CAC was performed 15 minutes after drop instillation. Nasal Congestion was assessed by the patient on a 0-4 scale (0=none to 4=severe). Nasal Congestion score for each time point was analyzed.

    Time frame: 7, 15, 20 minutes post-CAC

  28. Nasal Composite Score at Duration of Action (16 Hours Post-dose)

    A nasal composite score was summed for each patient based on the presence of at least one of the following four nasal symptoms on a 0-4 scale (0=none to 4=severe): rhinorrhea; nasal pruritus; ear or palate pruritus; and nasal congestion. The percentage of subjects with at least one nasal symptom present was calculated for each time point.

    Time frame: 7, 15, 20 minutes post-CAC

  29. Nasal Composite Score at Duration of Action (24 Hours Post-dose)

    A nasal composite score was summed for each patient based on the presence of at least one of the following four nasal symptoms on a 0-4 scale (0=none to 4=severe): rhinorrhea; nasal pruritus; ear or palate pruritus; and nasal congestion. The percentage of subjects with at least one nasal symptom present was calculated for each time point.

    Time frame: 7, 15, 20 minutes post-CAC

  30. Nasal Composite Score at Onset of Action (15 Minutes Post-dose)

    A nasal composite score was summed for each patient based on the presence of at least one of the following four nasal symptoms on a 0-4 scale (0=none to 4=severe): rhinorrhea; nasal pruritus; ear or palate pruritus; and nasal congestion. The percentage of subjects with at least one nasal symptom present was calculated for each time point.

    Time frame: 7, 15, 20 minutes post-CAC

  31. Tolerability of Study Medication at Visit 3A

    Subjects were asked to rate the comfort of the drop in each eye upon instillation, at 1 minute, and at 2 minutes after instillation of study medication. The assessment used a 10-point scale with 0 as very comfortable and 10 as very uncomfortable. Higher scores represent a worse outcome..

    Time frame: upon instillation, 1 minute and 2 minutes post instillation

07

Results

Posted Aug 30, 2017

Participant flow

Subjects were recruited from one site in the US.

Participant flow — Overall Study
MilestoneAC-170 0.05%AC-170 0.1%AC-170 0.24%AC-170 0%
Started25262525
Completed23252125
Not completed2140

Outcome measures

PrimaryOcular Itching at Duration of Action (16 Hours Post-dose)

A treatment efficacy CAC was performed 16 hours after drop instillation. Ocular itching was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of ocular itching score over both eyes was analyzed.

Time frame:
3, 5, 7 minutes post-CAC
Reported as:
Mean · units on a scale
Ocular Itching at Duration of Action (16 Hours Post-dose)
units on a scaleAC-170 0.05%AC-170 0.1%AC-170 0.24%AC-170 0%
3 minutes post-CAC1.91 ± 0.9242.00 ± 0.7711.65 ± 0.9632.48 ± 0.540
5 minutes post-CAC2.01 ± 1.0192.04 ± 0.8891.74 ± 0.8432.55 ± 0.550
7 minutes post-CAC1.86 ± 0.9071.87 ± 0.9131.75 ± 0.9102.27 ± 0.777
PrimaryOcular Itching at Duration of Action (24 Hours Post-dose)

A treatment efficacy CAC was performed 24 hours after drop instillation. Ocular itching was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of ocular itching score over both eyes was analyzed.

Time frame:
3, 5, 7 minutes post-CAC
Reported as:
Mean · units on a scale
Ocular Itching at Duration of Action (24 Hours Post-dose)
units on a scaleAC-170 0.05%AC-170 0.1%AC-170 0.24%AC-170 0%
3 minutes post-CAC1.99 ± 0.8491.78 ± 0.8731.90 ± 0.8042.24 ± 0.575
5 minutes post-CAC2.00 ± 0.7111.92 ± 0.8832.17 ± 0.8192.24 ± 0.686
7 minutes post-CAC1.77 ± 0.7741.78 ± 0.9881.97 ± 0.8332.08 ± 0.702
PrimaryOcular Itching at Onset of Action (15 Minutes Post-dose)

A treatment efficacy CAC was performed 15 minutes after drop instillation. Ocular itching was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of ocular itching score over both eyes was analyzed.

Time frame:
3, 5, 7 minutes post-CAC
Reported as:
Mean · units on a scale
Ocular Itching at Onset of Action (15 Minutes Post-dose)
units on a scaleAC-170 0.05%AC-170 0.1%AC-170 0.24%AC-170 0%
3 minutes post-CAC1.05 ± 0.8040.84 ± 0.8000.91 ± 0.8101.94 ± 0.870
5 minutes post-CAC1.19 ± 0.7781.09 ± 0.9411.07 ± 0.8402.09 ± 0.850
7 minutes post-CAC1.01 ± 0.7891.07 ± 0.9290.97 ± 0.8431.94 ± 0.893
PrimaryConjunctival Redness at Duration of Action (16 Hours Post-dose)

A treatment efficacy CAC was performed 16 hours after drop instillation. Conjunctival Redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of conjunctival redness score over both eyes was analyzed.

Time frame:
7, 15, 20 minutes post-CAC
Reported as:
Mean · units on a scale
Conjunctival Redness at Duration of Action (16 Hours Post-dose)
units on a scaleAC-170 0.05%AC-170 0.1%AC-170 0.24%AC-170 0%
7 minutes post-CAC1.62 ± 0.6341.59 ± 0.6241.45 ± 0.4891.79 ± 0.359
15 minutes post-CAC1.68 ± 0.6061.65 ± 0.7111.61 ± 0.5451.91 ± 0.426
20 minutes post-CAC1.63 ± 0.6961.58 ± 0.7211.56 ± 0.6341.88 ± 0.403
PrimaryConjunctival Redness at Duration of Action (24 Hours Post-dose)

A treatment efficacy CAC was performed 24 hours after drop instillation. Conjunctival Redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of conjunctival redness score over both eyes was analyzed.

Time frame:
7, 15, 20 minutes post-CAC
Reported as:
Mean · units on a scale
Conjunctival Redness at Duration of Action (24 Hours Post-dose)
units on a scaleAC-170 0.05%AC-170 0.1%AC-170 0.24%AC-170 0%
7 minutes post-CAC1.43 ± 0.6351.38 ± 0.6681.71 ± 0.6281.70 ± 0.505
15 minutes post-CAC1.63 ± 0.6171.59 ± 0.6631.85 ± 0.6081.90 ± 0.489
20 minutes post-CAC1.61 ± 0.6171.54 ± 0.6771.79 ± 0.7131.76 ± 0.575
PrimaryConjunctival Redness at Onset of Action (15 Minutes Post-dose)

A treatment efficacy CAC was performed 15 minutes after drop instillation. Conjunctival Redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of conjunctival redness score over both eyes was analyzed.

Time frame:
7, 15, 20 minutes post-CAC
Reported as:
Mean · units on a scale
Conjunctival Redness at Onset of Action (15 Minutes Post-dose)
units on a scaleAC-170 0.05%AC-170 0.1%AC-170 0.24%AC-170 0%
7 minutes post-CAC1.44 ± 0.6631.45 ± 0.8121.66 ± 0.7181.88 ± 0.541
15 minutes post-CAC1.81 ± 0.6701.67 ± 0.8211.83 ± 0.6801.96 ± 0.589
20 minutes post-CAC1.83 ± 0.6481.67 ± 0.8681.79 ± 0.7171.97 ± 0.622
SecondaryCiliary Redness at Duration of Action (16 Hours Post-dose)

A treatment efficacy CAC was performed 16 hours after drop instillation. Ciliary Redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of ciliary redness score over both eyes was analyzed.

Time frame:
7, 15, 20 minutes post-CAC
Reported as:
Mean · units on a scale
Ciliary Redness at Duration of Action (16 Hours Post-dose)
units on a scaleAC-170 0.05%AC-170 0.1%AC-170 0.24%AC-170 0%
7 minutes post-CAC1.47 ± 0.7081.53 ± 0.7581.34 ± 0.6841.81 ± 0.527
15 minutes post-CAC1.60 ± 0.7071.65 ± 0.8421.52 ± 0.7321.99 ± 0.523
20 minutes post-CAC1.60 ± 0.7031.65 ± 0.8781.53 ± 0.7881.95 ± 0.573
SecondaryCiliary Redness at Duration of Action (24 Hours Post-dose)

A treatment efficacy CAC was performed 24 hours after drop instillation. Ciliary Redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of ciliary redness score over both eyes was analyzed.

Time frame:
7, 15, 20 minutes post-CAC
Reported as:
Mean · units on a scale
Ciliary Redness at Duration of Action (24 Hours Post-dose)
units on a scaleAC-170 0.05%AC-170 0.1%AC-170 0.24%AC-170 0%
7 minutes post-CAC1.36 ± 0.7301.22 ± 0.6861.50 ± 0.6331.55 ± 0.582
15 minutes post-CAC1.49 ± 0.5961.47 ± 0.7231.74 ± 0.7161.77 ± 0.544
20 minutes post-CAC1.50 ± 0.6171.47 ± 0.7011.65 ± 0.7361.65 ± 0.599
SecondaryCiliary Redness at Onset of Action (15 Minutes Post-dose)

A treatment efficacy CAC was performed 15 minutes after drop instillation. Ciliary Redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of ciliary redness score over both eyes was analyzed.

Time frame:
7, 15, 20 minutes post-CAC
Reported as:
Mean · units on a scale
Ciliary Redness at Onset of Action (15 Minutes Post-dose)
units on a scaleAC-170 0.05%AC-170 0.1%AC-170 0.24%AC-170 0%
7 minutes post-CAC1.24 ± 0.6891.24 ± 0.8671.27 ± 0.8581.67 ± 0.628
15 minutes post-CAC1.59 ± 0.7491.51 ± 0.8611.64 ± 0.6691.77 ± 0.661
20 minutes post-CAC1.65 ± 0.6471.52 ± 0.9521.73 ± 0.6221.79 ± 0.644
SecondaryEpiscleral Redness at Duration of Action (16 Hours Post-dose)

A treatment efficacy CAC was performed 16 hours after drop instillation. Episcleral Redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of episcleral redness score over both eyes was analyzed.

Time frame:
7, 15, 20 minutes post-CAC
Reported as:
Mean · units on a scale
Episcleral Redness at Duration of Action (16 Hours Post-dose)
units on a scaleAC-170 0.05%AC-170 0.1%AC-170 0.24%AC-170 0%
7 minutes post-CAC1.68 ± 0.6021.74 ± 0.6901.57 ± 0.4971.90 ± 0.439
15 minutes post-CAC1.81 ± 0.6391.77 ± 0.7571.69 ± 0.6052.02 ± 0.484
20 minutes post-CAC1.80 ± 0.6291.73 ± 0.7971.69 ± 0.6471.97 ± 0.458
SecondaryEpiscleral Redness at Duration of Action (24 Hours Post-dose)

A treatment efficacy CAC was performed 24 hours after drop instillation. Episcleral Redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of episcleral redness score over both eyes was analyzed.

Time frame:
7, 15, 20 minutes post-CAC
Reported as:
Mean · units on a scale
Episcleral Redness at Duration of Action (24 Hours Post-dose)
units on a scaleAC-170 0.05%AC-170 0.1%AC-170 0.24%AC-170 0%
7 minutes post-CAC1.53 ± 0.5901.37 ± 0.6811.73 ± 0.6161.80 ± 0.505
15 minutes post-CAC1.72 ± 0.5851.63 ± 0.7001.90 ± 0.6572.00 ± 0.505
20 minutes post-CAC1.70 ± 0.5791.60 ± 0.6881.87 ± 0.6961.85 ± 0.530
SecondaryEpiscleral Redness at Onset of Action (15 Minutes Post-dose)

A treatment efficacy CAC was performed 15 minutes after drop instillation. Episcleral Redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of episcleral redness score over both eyes was analyzed.

Time frame:
7, 15, 20 minutes post-CAC
Reported as:
Mean · units on a scale
Episcleral Redness at Onset of Action (15 Minutes Post-dose)
units on a scaleAC-170 0.05%AC-170 0.1%AC-170 0.24%AC-170 0%
7 minutes post-CAC1.52 ± 0.6441.49 ± 0.7821.64 ± 0.7441.93 ± 0.508
15 minutes post-CAC1.86 ± 0.6521.73 ± 0.8031.98 ± 0.6982.01 ± 0.575
20 minutes post-CAC1.91 ± 0.5771.72 ± 0.8611.88 ± 0.6442.04 ± 0.598
SecondaryChemosis at Duration of Action (16 Hours Post-dose)

A treatment efficacy CAC was performed 16 hours after drop instillation. Chemosis was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of chemosis score over both eyes was analyzed.

Time frame:
7, 15, 20 minutes post-CAC
Reported as:
Mean · units on a scale
Chemosis at Duration of Action (16 Hours Post-dose)
units on a scaleAC-170 0.05%AC-170 0.1%AC-170 0.24%AC-170 0%
7 minutes post-CAC0.71 ± 0.5530.58 ± 0.4060.53 ± 0.2920.72 ± 0.532
15 minutes post-CAC0.93 ± 0.5570.70 ± 0.5450.60 ± 0.3540.99 ± 0.575
20 minutes post-CAC0.92 ± 0.6440.72 ± 0.5830.71 ± 0.4601.00 ± 0.650
SecondaryChemosis at Duration of Action (24 Hours Post-dose)

A treatment efficacy CAC was performed 24 hours after drop instillation. Chemosis was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of chemosis score over both eyes was analyzed.

Time frame:
7, 15, 20 minutes post-CAC
Reported as:
Mean · units on a scale
Chemosis at Duration of Action (24 Hours Post-dose)
units on a scaleAC-170 0.05%AC-170 0.1%AC-170 0.24%AC-170 0%
7 minutes post-CAC0.68 ± 0.4780.52 ± 0.2790.55 ± 0.2980.68 ± 0.399
15 minutes post-CAC0.87 ± 0.6120.64 ± 0.3960.77 ± 0.4330.81 ± 0.532
20 minutes post-CAC0.90 ± 0.6470.71 ± 0.4190.84 ± 0.5720.90 ± 0.568
SecondaryChemosis at Onset of Action (15 Minutes Post-dose)

A treatment efficacy CAC was performed 15 minutes after drop instillation. Chemosis was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of chemosis score over both eyes was analyzed.

Time frame:
7, 15, 20 minutes post-CAC
Reported as:
Mean · units on a scale
Chemosis at Onset of Action (15 Minutes Post-dose)
units on a scaleAC-170 0.05%AC-170 0.1%AC-170 0.24%AC-170 0%
7 minutes post-CAC0.49 ± 0.2320.43 ± 0.2930.54 ± 0.2770.74 ± 0.427
15 minutes post-CAC0.74 ± 0.4230.52 ± 0.3140.79 ± 0.4560.80 ± 0.554
20 minutes post-CAC0.71 ± 0.4030.53 ± 0.3630.76 ± 0.3990.88 ± 0.555
SecondaryEyelid Swelling at Duration of Action (16 Hours Post-dose)

A treatment efficacy CAC was performed 16 hours after drop instillation. Eyelid swelling was assessed by the patient on a 0-3 scale (0=none to 3=severe). Average of eyelid swelling score over both eyes was analyzed.

Time frame:
7, 15, 20 minutes post-CAC
Reported as:
Mean · units on a scale
Eyelid Swelling at Duration of Action (16 Hours Post-dose)
units on a scaleAC-170 0.05%AC-170 0.1%AC-170 0.24%AC-170 0%
7 minutes post-CAC0.6 ± 0.750.8 ± 0.660.8 ± 0.660.9 ± 0.71
15 minutes post-CAC0.7 ± 0.790.9 ± 0.750.8 ± 0.541.1 ± 0.86
20 minutes post-CAC0.6 ± 0.760.8 ± 0.730.7 ± 0.561.0 ± 0.85
SecondaryEyelid Swelling at Duration of Action (24 Hours Post-dose)

A treatment efficacy CAC was performed 24 hours after drop instillation. Eyelid swelling was assessed by the patient on a 0-3 scale (0=none to 3=severe). Average of eyelid swelling score over both eyes was analyzed.

Time frame:
7, 15, 20 minutes post-CAC
Reported as:
Mean · units on a scale
Eyelid Swelling at Duration of Action (24 Hours Post-dose)
units on a scaleAC-170 0.05%AC-170 0.1%AC-170 0.24%AC-170 0%
7 minutes post-CAC0.7 ± 0.600.7 ± 0.540.9 ± 0.680.7 ± 0.74
15 minutes post-CAC0.8 ± 0.700.8 ± 0.730.9 ± 0.820.9 ± 0.82
20 minutes post-CAC0.8 ± 0.690.8 ± 0.760.9 ± 0.720.9 ± 0.85
SecondaryEyelid Swelling at Onset of Action (15 Minutes Post-dose)

A treatment efficacy CAC was performed 15 minutes after drop instillation. Eyelid swelling was assessed by the patient on a 0-3 scale (0=none to 3=severe). Average of eyelid swelling score over both eyes was analyzed.

Time frame:
7, 15, 20 minutes post-CAC
Reported as:
Mean · units on a scale
Eyelid Swelling at Onset of Action (15 Minutes Post-dose)
units on a scaleAC-170 0.05%AC-170 0.1%AC-170 0.24%AC-170 0%
7 minutes post-CAC0.4 ± 0.560.5 ± 0.700.5 ± 0.490.7 ± 0.81
15 minutes post-CAC0.5 ± 0.680.6 ± 0.650.6 ± 0.650.8 ± 0.89
20 minutes post-CAC0.5 ± 0.710.6 ± 0.580.5 ± 0.490.7 ± 0.84
SecondaryTearing at Duration of Action (16 Hours Post-dose)

A treatment efficacy CAC was performed 16 hours after drop instillation. Tearing was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of tearing score over both eyes was analyzed.

Time frame:
7, 15, 20 minutes post-CAC
Reported as:
Mean · units on a scale
Tearing at Duration of Action (16 Hours Post-dose)
units on a scaleAC-170 0.05%AC-170 0.1%AC-170 0.24%AC-170 0%
7 minutes post-CAC1.0 ± 1.070.8 ± 0.720.6 ± 0.510.6 ± 0.67
15 minutes post-CAC0.8 ± 0.890.5 ± 0.640.7 ± 0.650.9 ± 0.82
20 minutes post-CAC0.7 ± 0.850.4 ± 0.630.7 ± 0.620.9 ± 0.97
SecondaryTearing at Duration of Action (24 Hours Post-dose)

A treatment efficacy CAC was performed 24 hours after drop instillation. Tearing was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of tearing score over both eyes was analyzed.

Time frame:
7, 15, 20 minutes post-CAC
Reported as:
Mean · units on a scale
Tearing at Duration of Action (24 Hours Post-dose)
units on a scaleAC-170 0.05%AC-170 0.1%AC-170 0.24%AC-170 0%
7 minutes post-CAC1.0 ± 0.780.7 ± 0.610.6 ± 0.750.8 ± 0.71
15 minutes post-CAC1.1 ± 0.790.6 ± 0.540.7 ± 0.660.8 ± 0.82
20 minutes post-CAC1.0 ± 0.770.5 ± 0.530.7 ± 0.720.7 ± 0.84
SecondaryTearing at Onset of Action (15 Minutes Post-dose)

A treatment efficacy CAC was performed 15 minutes after drop instillation. Tearing was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of tearing score over both eyes was analyzed.

Time frame:
7, 15, 20 minutes post-CAC
Reported as:
Mean · units on a scale
Tearing at Onset of Action (15 Minutes Post-dose)
units on a scaleAC-170 0.05%AC-170 0.1%AC-170 0.24%AC-170 0%
7 minutes post-CAC0.7 ± 0.740.5 ± 0.490.3 ± 0.560.6 ± 0.64
15 minutes post-CAC0.5 ± 0.660.5 ± 0.500.4 ± 0.500.6 ± 0.64
20 minutes post-CAC0.5 ± 0.600.4 ± 0.470.2 ± 0.330.6 ± 0.90
SecondaryRhinorrhea at Duration of Action (16 Hours Post-dose)

A treatment efficacy CAC was performed 16 hours after drop instillation. Rhinorrhea was assessed by the patient on a 0-4 scale (0=none to 4=severe). Rhinorrhea score for each time point was analyzed.

Time frame:
7, 15, 20 minutes post-CAC
Reported as:
Mean · units on a scale
Rhinorrhea at Duration of Action (16 Hours Post-dose)
units on a scaleAC-170 0.05%AC-170 0.1%AC-170 0.24%AC-170 0%
7 minutes post-CAC1.1 ± 1.260.4 ± 0.490.7 ± 0.990.7 ± 0.80
15 minutes post-CAC1.2 ± 1.010.6 ± 0.771.1 ± 1.041.0 ± 1.12
20 minutes post-CAC1.3 ± 1.140.7 ± 0.801.1 ± 1.051.1 ± 1.24
SecondaryRhinorrhea at Duration of Action (24 Hours Post-dose)

A treatment efficacy CAC was performed 24 hours after drop instillation. Rhinorrhea was assessed by the patient on a 0-4 scale (0=none to 4=severe). Rhinorrhea score for each time point was analyzed.

Time frame:
7, 15, 20 minutes post-CAC
Reported as:
Mean · units on a scale
Rhinorrhea at Duration of Action (24 Hours Post-dose)
units on a scaleAC-170 0.05%AC-170 0.1%AC-170 0.24%AC-170 0%
7 minutes post-CAC1.1 ± 1.280.6 ± 0.650.8 ± 0.900.7 ± 0.69
15 minutes post-CAC1.1 ± 1.290.7 ± 0.691.2 ± 0.911.0 ± 0.84
20 minutes post-CAC1.2 ± 1.280.6 ± 0.701.0 ± 0.710.8 ± 0.90
SecondaryRhinorrhea at Onset of Action (15 Minutes Post-dose)

A treatment efficacy CAC was performed 15 minutes after drop instillation. Rhinorrhea was assessed by the patient on a 0-4 scale (0=none to 4=severe). Rhinorrhea score for each time point was analyzed.

Time frame:
7, 15, 20 minutes post-CAC
Reported as:
Mean · units on a scale
Rhinorrhea at Onset of Action (15 Minutes Post-dose)
units on a scaleAC-170 0.05%AC-170 0.1%AC-170 0.24%AC-170 0%
7 minutes post-CAC0.6 ± 1.200.2 ± 0.410.3 ± 0.580.6 ± 0.82
15 minutes post-CAC0.9 ± 1.250.4 ± 0.650.5 ± 0.750.8 ± 0.87
20 minutes post-CAC0.8 ± 1.230.4 ± 0.710.5 ± 0.680.6 ± 0.70
SecondaryNasal Pruritus at Duration of Action (16 Hours Post-dose)

A treatment efficacy CAC was performed 16 hours after drop instillation. Nasal Pruritus was assessed by the patient on a 0-4 scale (0=none to 4=severe). Nasal Pruritus score for each time point was analyzed.

Time frame:
7, 15, 20 minutes post-CAC
Reported as:
Mean · units on a scale
Nasal Pruritus at Duration of Action (16 Hours Post-dose)
units on a scaleAC-170 0.05%AC-170 0.1%AC-170 0.24%AC-170 0%
7 minutes post-CAC0.6 ± 0.910.2 ± 0.370.5 ± 0.650.4 ± 0.71
15 minutes post-CAC0.6 ± 0.910.4 ± 0.650.7 ± 0.800.8 ± 1.01
20 minutes post-CAC0.7 ± 0.990.6 ± 0.910.6 ± 0.650.8 ± 1.13
SecondaryNasal Pruritus at Duration of Action (24 Hours Post-dose)

A treatment efficacy CAC was performed 24 hours after drop instillation. Nasal Pruritus was assessed by the patient on a 0-4 scale (0=none to 4=severe). Nasal Pruritus score for each time point was analyzed.

Time frame:
7, 15, 20 minutes post-CAC
Reported as:
Mean · units on a scale
Nasal Pruritus at Duration of Action (24 Hours Post-dose)
units on a scaleAC-170 0.05%AC-170 0.1%AC-170 0.24%AC-170 0%
7 minutes post-CAC0.7 ± 0.930.4 ± 0.640.4 ± 0.580.4 ± 0.82
15 minutes post-CAC0.7 ± 1.030.4 ± 0.580.8 ± 0.930.6 ± 0.99
20 minutes post-CAC0.5 ± 0.900.5 ± 0.650.6 ± 0.820.7 ± 0.85
SecondaryNasal Pruritus at Onset of Action (15 Minutes Post-dose)

A treatment efficacy CAC was performed 15 minutes after drop instillation. Nasal Pruritus was assessed by the patient on a 0-4 scale (0=none to 4=severe). Nasal Pruritus score for each time point was analyzed.

Time frame:
7, 15, 20 minutes post-CAC
Reported as:
Mean · units on a scale
Nasal Pruritus at Onset of Action (15 Minutes Post-dose)
units on a scaleAC-170 0.05%AC-170 0.1%AC-170 0.24%AC-170 0%
7 minutes post-CAC0.4 ± 0.990.2 ± 0.370.3 ± 0.560.4 ± 0.65
15 minutes post-CAC0.4 ± 0.840.3 ± 0.560.2 ± 0.440.4 ± 0.58
20 minutes post-CAC0.4 ± 0.950.4 ± 0.640.3 ± 0.660.4 ± 0.65
SecondaryEar or Palate Pruritus at Duration of Action (16 Hours Post-dose)

A treatment efficacy CAC was performed 16 hours after drop instillation. Ear or Palate Pruritus was assessed by the patient on a single 0-4 scale (0=none to 4=severe). Ear or Palate Pruritus score for each time point was analyzed.

Time frame:
7, 15, 20 minutes post-CAC
Reported as:
Mean · units on a scale
Ear or Palate Pruritus at Duration of Action (16 Hours Post-dose)
units on a scaleAC-170 0.05%AC-170 0.1%AC-170 0.24%AC-170 0%
7 minutes post-CAC0.4 ± 0.870.4 ± 0.570.3 ± 0.740.5 ± 0.87
15 minutes post-CAC0.9 ± 1.090.8 ± 0.900.5 ± 0.771.0 ± 1.10
20 minutes post-CAC0.8 ± 1.110.9 ± 0.910.8 ± 0.931.2 ± 1.31
SecondaryEar or Palate Pruritus at Duration of Action (24 Hours Post-dose)

A treatment efficacy CAC was performed 24 hours after drop instillation. Ear or Palate Pruritus was assessed by the patient on a single 0-4 scale (0=none to 4=severe). Ear or Palate Pruritus score for each time point was analyzed.

Time frame:
7, 15, 20 minutes post-CAC
Reported as:
Mean · units on a scale
Ear or Palate Pruritus at Duration of Action (24 Hours Post-dose)
units on a scaleAC-170 0.05%AC-170 0.1%AC-170 0.24%AC-170 0%
7 minutes post-CAC0.6 ± 0.890.3 ± 0.460.4 ± 0.760.5 ± 0.96
15 minutes post-CAC0.7 ± 0.960.6 ± 0.650.7 ± 0.980.8 ± 1.19
20 minutes post-CAC0.8 ± 1.110.7 ± 0.740.7 ± 0.900.7 ± 1.07
SecondaryEar or Palate Pruritus at Onset of Action (15 Minutes Post-dose)

A treatment efficacy CAC was performed 15 minutes after drop instillation. Ear or Palate Pruritus was assessed by the patient on a single 0-4 scale (0=none to 4=severe). Ear or Palate Pruritus score for each time point was analyzed.

Time frame:
7, 15, 20 minutes post-CAC
Reported as:
Mean · units on a scale
Ear or Palate Pruritus at Onset of Action (15 Minutes Post-dose)
units on a scaleAC-170 0.05%AC-170 0.1%AC-170 0.24%AC-170 0%
7 minutes post-CAC0.6 ± 0.990.2 ± 0.520.3 ± 0.560.4 ± 0.76
15 minutes post-CAC08 ± 0.950.4 ± 0.760.3 ± 0.580.7 ± 1.07
20 minutes post-CAC0.7 ± 1.010.5 ± 0.770.3 ± 0.580.7 ± 1.07
SecondaryNasal Congestion at Onset of Action (16 Hours Post-dose)

A treatment efficacy CAC was performed 16 hours after drop instillation. Nasal Congestion was assessed by the patient on a 0-4 scale (0=none to 4=severe). Nasal Congestion score for each time point was analyzed.

Time frame:
7, 15, 20 minutes post-CAC
Reported as:
Mean · units on a scale
Nasal Congestion at Onset of Action (16 Hours Post-dose)
units on a scaleAC-170 0.05%AC-170 0.1%AC-170 0.24%AC-170 0%
7 minutes post-CAC1.2 ± 0.990.5 ± 0.650.8 ± 1.180.8 ± 0.78
15 minutes post-CAC1.4 ± 1.040.6 ± 0.761.0 ± 1.191.2 ± 0.85
20 minutes post-CAC1.5 ± 1.050.8 ± 0.991.0 ± 1.141.3 ± 1.21
SecondaryNasal Congestion at Duration of Action (24 Hours Post-dose)

A treatment efficacy CAC was performed 24 hours after drop instillation. Nasal Congestion was assessed by the patient on a 0-4 scale (0=none to 4=severe). Nasal Congestion score for each time point was analyzed.

Time frame:
7, 15, 20 minutes post-CAC
Reported as:
Mean · units on a scale
Nasal Congestion at Duration of Action (24 Hours Post-dose)
units on a scaleAC-170 0.05%AC-170 0.1%AC-170 0.24%AC-170 0%
7 minutes post-CAC0.9 ± 0.970.6 ± 0.580.8 ± 0.800.7 ± 0.69
15 minutes post-CAC1.2 ± 0.980.6 ± 0.581.2 ± 0.941.1 ± 0.83
20 minutes post-CAC1.2 ± 1.000.6 ± 0.651.1 ± 1.041.2 ± 0.88
SecondaryNasal Congestion at Onset of Action (15 Minutes Post-dose)

A treatment efficacy CAC was performed 15 minutes after drop instillation. Nasal Congestion was assessed by the patient on a 0-4 scale (0=none to 4=severe). Nasal Congestion score for each time point was analyzed.

Time frame:
7, 15, 20 minutes post-CAC
Reported as:
Mean · units on a scale
Nasal Congestion at Onset of Action (15 Minutes Post-dose)
units on a scaleAC-170 0.05%AC-170 0.1%AC-170 0.24%AC-170 0%
7 minutes post-CAC0.7 ± 1.050.4 ± 0.580.4 ± 0.590.8 ± 0.78
15 minutes post-CAC1.1 ± 1.080.5 ± 0.650.4 ± 0.591.4 ± 0.86
20 minutes post-CAC1.1 ± 1.140.5 ± 0.650.4 ± 0.591.4 ± 0.87
SecondaryNasal Composite Score at Duration of Action (16 Hours Post-dose)

A nasal composite score was summed for each patient based on the presence of at least one of the following four nasal symptoms on a 0-4 scale (0=none to 4=severe): rhinorrhea; nasal pruritus; ear or palate pruritus; and nasal congestion. The percentage of subjects with at least one nasal symptom present was calculated for each time point.

Time frame:
7, 15, 20 minutes post-CAC
Reported as:
Number · percentage of subjects
Nasal Composite Score at Duration of Action (16 Hours Post-dose)
percentage of subjectsAC-170 0.05%AC-170 0.1%AC-170 0.24%AC-170 0%
7 minutes post-CAC82.666.752.476.0
15 minutes post-CAC82.679.290.584.0
20 minutes post-CAC91.383.395.284.0
SecondaryNasal Composite Score at Duration of Action (24 Hours Post-dose)

A nasal composite score was summed for each patient based on the presence of at least one of the following four nasal symptoms on a 0-4 scale (0=none to 4=severe): rhinorrhea; nasal pruritus; ear or palate pruritus; and nasal congestion. The percentage of subjects with at least one nasal symptom present was calculated for each time point.

Time frame:
7, 15, 20 minutes post-CAC
Reported as:
Number · percentage of subjects
Nasal Composite Score at Duration of Action (24 Hours Post-dose)
percentage of subjectsAC-170 0.05%AC-170 0.1%AC-170 0.24%AC-170 0%
7 minutes post-CAC69.676.085.768.0
15 minutes post-CAC82.684.090.592.0
20 minutes post-CAC82.688.081.092.0
SecondaryNasal Composite Score at Onset of Action (15 Minutes Post-dose)

A nasal composite score was summed for each patient based on the presence of at least one of the following four nasal symptoms on a 0-4 scale (0=none to 4=severe): rhinorrhea; nasal pruritus; ear or palate pruritus; and nasal congestion. The percentage of subjects with at least one nasal symptom present was calculated for each time point.

Time frame:
7, 15, 20 minutes post-CAC
Reported as:
Number · percentage of subjects
Nasal Composite Score at Onset of Action (15 Minutes Post-dose)
percentage of subjectsAC-170 0.05%AC-170 0.1%AC-170 0.24%AC-170 0%
7 minutes post-CAC52.25647.672
15 minutes post-CAC82.65647.684
20 minutes post-CAC73.95252.484
SecondaryTolerability of Study Medication at Visit 3A

Subjects were asked to rate the comfort of the drop in each eye upon instillation, at 1 minute, and at 2 minutes after instillation of study medication. The assessment used a 10-point scale with 0 as very comfortable and 10 as very uncomfortable. Higher scores represent a worse outcome..

Time frame:
upon instillation, 1 minute and 2 minutes post instillation
Reported as:
Mean · units on a scale
Tolerability of Study Medication at Visit 3A
units on a scaleAC-170 0.05%AC-170 0.1%AC-170 0.24%AC-170 0%
Upon instillation0.5 ± 0.950.7 ± 1.041.3 ± 1.930.6 ± 1.03
1 minute post-instillation0.7 ± 1.130.9 ± 1.132.0 ± 2.250.9 ± 1.18
2 minutes post-instillation0.8 ± 1.101.0 ± 1.181.7 ± 2.270.6 ± 0.79

Adverse events

Collected over Adverse events were assessed through study completion, approximately two months. All subjects who received study medication were evaluable for the safety analysis.. Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
AC-170 0.05%—0/25 (0%)6/25 (24%)
AC-170 0.1%—0/26 (0%)3/26 (11.5%)
AC-170 0.24%—0/25 (0%)4/25 (16%)
AC-170 0%—0/25 (0%)2/25 (8%)
Most frequent other events
Showing 10 of 12
Most frequent other events
EventAC-170 0.05%AC-170 0.1%AC-170 0.24%AC-170 0%
Visual acuity reducsedEye disorders2/251/260/251/25
PhotophobiaEye disorders0/250/261/250/25
PetechiaeSkin and subcutaneous tissue disorders0/250/260/251/25
Dermatitis contactSkin and subcutaneous tissue disorders0/250/261/250/25
Back painMusculoskeletal and connective tissue disorders1/250/260/250/25
Oral pruritusGastrointestinal disorders1/250/260/250/25
Palatal OedemaGastrointestinal disorders1/250/260/250/25
NasopharyngitisInfections and infestations1/250/260/250/25
HeadacheNervous system disorders0/250/261/250/25
EpistaxisRespiratory, thoracic and mediastinal disorders0/250/261/250/25

Baseline characteristics

Age, Continuous
Age, Continuous(years)AC-170 0.05%AC-170 0.1%AC-170 0.24%AC-170 0%Total
Mean45.5 ± 13.5843.1 ± 13.538.9 ± 12.5338.1 ± 14.1241.4 ± 13.59
Sex: Female, Male
Sex: Female, Male(Participants)AC-170 0.05%AC-170 0.1%AC-170 0.24%AC-170 0%Total
Female1715101456
Male811151145
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)AC-170 0.05%AC-170 0.1%AC-170 0.24%AC-170 0%Total
Hispanic or Latino353516
Not Hispanic or Latino2221222085
Unknown or Not Reported00000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)AC-170 0.05%AC-170 0.1%AC-170 0.24%AC-170 0%Total
American Indian or Alaska Native00000
Asian00011
Native Hawaiian or Other Pacific Islander00000
Black or African American11114
White2425242396
More than one race00000
Unknown or Not Reported00000
Region of Enrollment
Region of Enrollment(participants)AC-170 0.05%AC-170 0.1%AC-170 0.24%AC-170 0%Total
United States25262525101
08

Study locations

1 site
  • Ora, Inc.
    Andover, Massachusetts 01810, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2011, a primary completion of Jun 2011 and a completion of Oct 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2017, 6 years 2 months after primary completion. A results delay was requested in Jul 2012.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 7, 2011
First posted
Apr 11, 2011
Start
Apr 2011
Primary completionActual
Jun 2011
CompletionActual
Oct 2011
Results delay requested
Jul 10, 2012
Results first posted
Aug 30, 2017
Last update
Aug 30, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 30, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01332188
Lead sponsor
Aciex Therapeutics, Inc.
Responsible party
Sponsor
First posted
Apr 11, 2011
Start date
Apr 2011
Primary completion
Jun 2011
Completion
Oct 2011
Results posted
Aug 30, 2017
Last update
Aug 30, 2017

Study contacts

Gail L Torkildsen, MD
principal investigator · Andover Eye Associates

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cetirizine

Start the discussion